RxDoctor Payments Data

David Hersh, MD

Cardiovascular Disease · Woodmere, NYNPI 1588854921

Payments from drug & device makers

$2,185in general payments, 2019–2025

Across 124 payments — averaging $17.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$377
  • Novo Nordisk$371
  • AstraZeneca$254
  • Johnson & Johnson$195
  • Novartis$139
  • Edwards Lifesciences$117
  • plus $732 from 16 others

What the payments were for

  • Food & beverage$2,16699%
  • Education$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,185 in reported general payments places this provider in the 55th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$309,245
Medicare patients
285
Services billed
2,419

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban61$62,289
EntrestoSacubitril/Valsartan22$42,795
XareltoRivaroxaban43$40,168
OzempicSemaglutide36$33,702
BrilintaTicagrelor26$23,320
JanuviaSitagliptin Phosphate15$12,355
Pitavastatin Calcium14$2,982
Atorvastatin Calcium254$2,453
Nebivolol Hcl35$2,322
Metoprolol Succinate170$2,115
Losartan Potassium170$1,422
Amlodipine Besylate269$1,356
Ezetimibe30$1,028
Carvedilol73$670
SynthroidLevothyroxine Sodium14$562

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$89$62,28961 claims
NovartisEntresto$139$42,79522 claims
Johnson & JohnsonXarelto$195$40,16843 claims
Novo NordiskOzempic$371$33,70236 claims
AstraZenecaBrilinta$254$23,32026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Woodmere

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →